CoMind

CoMind Technologies Limited is pioneering non-invasive neurotechnology to transform clinical brain monitoring. The company recently announced a significant $102.5 million funding round to advance its platform, which aims to provide clinicians with unprecedented access to multiple neurophysiological signals through a single, simple measurement. Their focus is on addressing critical unmet needs in neurological care by harnessing photonics technology to improve patient outcomes.

A non-invasive, photonics-based bedside platform designed to measure a comprehensive range of neurophysiological signals from a single measurement point, providing clinicians with previously inaccessible brain data.

CoMind competes with established medical device companies (Medtronic, Natus) offering EEG and limited optical monitoring, as well as emerging neurotech startups. Their differentiation lies in the promise of a comprehensive, multi-parameter bedside monitor using photonics to access signals currently unavailable with non-invasive methods.